The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Management of the adverse effects associated with intravenous bisphosphonates
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Case Report and Literature Review
Spoden, J. E., Bumsted, R. M., & Warner, E. D. (1980) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348948008900320 · Cited by 1,094
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Osteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.105 · Cited by 729
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
Bisphosphanates and Oral Cavity Avascular Bone Necrosis
Migliorati, C. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.132 · Cited by 480
Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
MARKOWITZ, G. S., APPEL, G. B., FINE, P. L., FENVES, A. Z., LOON, N. R., JAGANNATH, S., KUHN, J. A., DRATCH, A. D., & D'AGATI, V. D. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261164 · Cited by 466
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Body, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg367 · Cited by 413
γ/δ T-Cell Stimulation by Pamidronate
Kunzmann, V., Bauer, E., & Wilhelm, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400914 · Cited by 395
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
Markowitz, G. S., Fine, P. L., Stack, J. I., Kunis, C. L., Radhakrishnan, J., Palecki, W., Park, J., Nasr, S. H., Hoh, S., Siegel, D. S., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00071.x · Cited by 384
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491316 · Cited by 374
Renal Failure with the Use of Zoledronic Acid
(2003) · New England Journal of Medicine · doi:10.1056/nejm200310233491721 · Cited by 367
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Rosen, L. S., Gordon, D. H., Dugan, W., Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B., et al. (2004) · Cancer · doi:10.1002/cncr.11892 · Cited by 335
Detwiler, R. K., Falk, R. J., Hogan, S. L., & Jennette, J. C. (1994) · Kidney International · doi:10.1038/ki.1994.185 · Cited by 290
Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?
Hellstein, J. W., & Marek, C. L. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.01.010 · Cited by 270
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
Bagan, J. V., Murillo, J., Jimenez, Y., Poveda, R., Milian, M. A., Sanchis, J. M., Silvestre, F. J., & Scully, C. (2005) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2004.00269.x · Cited by 266
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
Conte, P., & Guarneri, V. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-28 · Cited by 241 · cited 1×
“Intravenous clodronate and etidronate are less potent, with less affinity to bone, requiring prolonged infusion time and thus becoming less popular [4].”
BackgroundOsteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment
Ficarra, G., Beninati, F., Rubino, I., Vannucchi, A., Longo, G., Tonelli, P., & Pini Prato, G. (2005) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00842.x · Cited by 210
Bisphosphonates and osteonecrosis of the jaw
Purcell, P. M., & Boyd, I. W. (2005) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06762.x · Cited by 202
Severe Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D Deficiency
Rosen, C. J., & Brown, S. (2003) · New England Journal of Medicine · doi:10.1056/nejm200304103481521 · Cited by 168
Bisphosphonates and avascular necrosis of the jaw: a possible association
Carter, G., Goss, A. N., & Doecke, C. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06761.x · Cited by 156
Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity
Lugassy, G., Shaham, R., Nemets, A., Ben‐Dor, D., & Nahlieli, O. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.015 · Cited by 136
Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.
Melo, M. D., & Obeid, G. (2005) · PubMed · Cited by 132
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., & Theriault, R. L. (2004) · Breast Diseases A Year Book Quarterly · Cited by 118
Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma
Vannucchi, A. M., Ficarra, G., Antonioli, E., & Bosi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05382.x · Cited by 109
Podocyte injury associated glomerulopathies induced by pamidronate
Barri, Y. M., Munshi, N. C., Sukumalchantra, S., Abul‐Ezz, S. R., Bonsib, S. M., Wallach, J., & Walker, P. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00426.x · Cited by 104
Severe hypocalcaemia after being given intravenous bisphosphonate
Peter, R., Mishra, V., & Fraser, W. D. (2004) · BMJ · doi:10.1136/bmj.328.7435.335 · Cited by 100
Lenz, J., Steiner-Krammer, B., Schmidt, W., Fietkau, R., Mueller, P. C., & Gundlach, K. K. H. (2005) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2005.07.007 · Cited by 93
Pfister, T., Atzpodien, E., & Bauss, F. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00257-9 · Cited by 92
Pecherstorfer, M., Steinhauer, E. U., Rizzoli, R., Wetterwald, M., & Bergstr�m, B. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0477-1 · Cited by 83
Katz, H. R. (2005) · Journal of Endodontics · doi:10.1097/01.don.0000186481.96169.cd · Cited by 79
Zoledronic Acid and Renal Toxicity: Data from French Adverse Effect Reporting Database
Munier, A., Gras, V., Andréjak, M., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e589 · Cited by 79
Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado, C., & Flombaum, C. D. (1996) · PubMed · Cited by 77
Major, P. P., & Coleman, R. E. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90261-1 · Cited by 77
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis
HAWORTH, C. S., Selby, P. L., Webb, A. K., Mawer, E. B., Adams, J. E., & Freemont, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79826-3 · Cited by 69
Pecherstorfer, M., Jilch, R., Sauty, A., Horn, E., Keck, A. V., Zimmer-Roth, I., & Thiébaud, D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.147 · Cited by 53
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid
Olson, K. B., Hellie, C. M., & Pienta, K. J. (2005) · Urology · doi:10.1016/j.urology.2005.03.028 · Cited by 48
Estilo, C. L., Poznak, C. H. V., Williams, T. L., Evtimovska, E., Tkach, L., Halpern, J., Tunick, S., & Huryn, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.8088 · Cited by 47
Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis
Lockridge, L., Papac, R. J., & Perazella, M. A. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33933 · Cited by 41
Pamidronate-induced nephrotoxic tubular necrosis – a case report
Smetana, S. S., Michlin, A., Rosenman, E., Biro, A., Boaz, M., & Katzir, Z. (2004) · Clinical Nephrology · doi:10.5414/cnp61063 · Cited by 41
Yates, A. J. P., Murray, R., Jerums, G., & Martin, T. J. (1987) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1987.tb00070.x · Cited by 33
Mishra, A., Wong, L. L., & Jonklaas, J. (2001) · Endocrine · doi:10.1385/endo:14:2:159 · Cited by 31
Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review.
Rey, J., Legré-Boyer, V., Pham, T., Bernard, P., Dahan, L., Acquaviva, P. C., & Lafforgue, P. (2000) · PubMed · Cited by 27
Jones, S. G., Dolan, G., Lengyel, K., & Myers, B. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03835_4.x · Cited by 25
Hypocalcemia and Azotemia Associated with Zoledronic Acid and Interferon Alfa
Tanvetyanon, T., & Choudhury, A. M. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d357 · Cited by 13
Self-citation
Cited by
Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
Mucha, A., Kafarski, P., & Berlicki, Ł. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200587f · Cited by 672
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · Hormones · doi:10.14310/horm.2002.1226 · Cited by 312
Bisphosphonates in multiple myeloma: a network meta-analysis
Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O. A. C., Miladinovic, B., Glasmacher, A., Kumar, A., & Djulbegovic, B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub3 · Cited by 130
Adrenal crisis after first infusion of zoledronic acid: a case report
Smrecnik, M., Kavcic Trsinar, Z., & Kocjan, T. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4508-7 · Cited by 11
Metadata
- Authors
- Tanvetyanon, T., & Stiff, P. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 17
- Issue
- 6
- Pages
- 897-907
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2154102227
- Cited by
- 301
- References
- 62
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.